X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (95703) 95703
Newspaper Article (63479) 63479
Newsletter (10435) 10435
Book Chapter (8316) 8316
Transcript (4142) 4142
Report (2502) 2502
Web Resource (2192) 2192
Trade Publication Article (785) 785
Magazine Article (778) 778
Patent (493) 493
Dissertation (224) 224
Reference (147) 147
Book / eBook (140) 140
Conference Proceeding (97) 97
Book Review (86) 86
Publication (73) 73
Government Document (22) 22
Streaming Video (3) 3
Presentation (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (60368) 60368
life sciences & biomedicine (58328) 58328
humans (52797) 52797
oncology (34051) 34051
clinical trials (26672) 26672
male (25399) 25399
cancer (25257) 25257
female (23665) 23665
middle aged (19177) 19177
care and treatment (17666) 17666
pharmaceutical industry (16378) 16378
adult (16179) 16179
aged (16044) 16044
research (15004) 15004
patients (14360) 14360
tumors (14055) 14055
drug dosages (13790) 13790
treatment outcome (12261) 12261
medical research (12175) 12175
animals (11316) 11316
pharmacology & pharmacy (10621) 10621
chemotherapy (10361) 10361
cancer therapies (9206) 9206
biotechnology industry (9195) 9195
radiotherapy (8951) 8951
medicine & public health (8882) 8882
drug therapy (8576) 8576
metastasis (8524) 8524
health aspects (8122) 8122
immunotherapy (7956) 7956
hematology (7875) 7875
stockholders (7325) 7325
studies (6889) 6889
hematology, oncology and palliative medicine (6673) 6673
radiology, nuclear medicine & medical imaging (6565) 6565
analysis (6515) 6515
earnings per share (6488) 6488
dose-response relationship, drug (6476) 6476
product development (6304) 6304
net losses (6198) 6198
prostate cancer (6006) 6006
aged, 80 and over (5925) 5925
research & development--r&d (5649) 5649
review (5529) 5529
antineoplastic agents - therapeutic use (5327) 5327
radiation therapy (5264) 5264
mutation (4989) 4989
medicine, experimental (4902) 4902
antineoplastic combined chemotherapy protocols - therapeutic use (4820) 4820
proteins (4735) 4735
breast cancer (4701) 4701
leukemia (4657) 4657
immunology (4575) 4575
lung cancer (4538) 4538
lymphomas (4424) 4424
medicine (4397) 4397
stock exchanges (4307) 4307
oncology, experimental (4258) 4258
adolescent (4235) 4235
abridged index medicus (3985) 3985
surgery (3920) 3920
radiotherapy dosage (3902) 3902
toxicity (3901) 3901
clinical trials as topic (3871) 3871
stem cells (3849) 3849
neoplasms - drug therapy (3800) 3800
prognosis (3710) 3710
medicine, research & experimental (3705) 3705
research & experimental medicine (3697) 3697
radiology (3657) 3657
mice (3653) 3653
young adult (3650) 3650
collaboration (3619) 3619
pharmacokinetics (3608) 3608
risk factors (3594) 3594
retrospective studies (3578) 3578
drug administration schedule (3577) 3577
neurosciences & neurology (3575) 3575
antineoplastic agents (3574) 3574
fda approval (3478) 3478
antimitotic agents (3364) 3364
antigens (3363) 3363
dosage and administration (3352) 3352
radiation (3302) 3302
pharmaceuticals (3295) 3295
drugs (3293) 3293
pharmacology (3257) 3257
usage (3250) 3250
gene therapy (3239) 3239
pharmacology/toxicology (3232) 3232
kinases (3213) 3213
internal medicine (3100) 3100
apoptosis (3079) 3079
webcasting (3073) 3073
neoplasm staging (2999) 2999
investments (2985) 2985
follow-up studies (2973) 2973
clinical neurology (2968) 2968
melanoma (2913) 2913
financial performance (2886) 2886
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (21) 21
Online Resources - Online (20) 20
Collection Dvlpm't (Acquisitions) - Vendor file (14) 14
Media Commons - Microtexts (10) 10
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (10) 10
Gerstein Science - Theses (3) 3
UofT at Mississauga - Stacks (2) 2
Lakeridge Health Sciences - Online (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - Stacks (1) 1
Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (188965) 188965
French (446) 446
German (227) 227
Japanese (122) 122
Korean (64) 64
Polish (56) 56
Portuguese (48) 48
Spanish (35) 35
Italian (31) 31
Chinese (29) 29
Russian (28) 28
Norwegian (18) 18
Hungarian (16) 16
Czech (8) 8
Dutch (7) 7
Arabic (6) 6
Danish (5) 5
Serbian (5) 5
Turkish (5) 5
Croatian (4) 4
Slovenian (3) 3
Urdu (3) 3
Lithuanian (2) 2
Swedish (2) 2
Belarusian (1) 1
Bulgarian (1) 1
Catalan (1) 1
Greek (1) 1
Hebrew (1) 1
Manx (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 16, pp. 3080 - 3087
...). In this phase 1 dose‐escalation study, the authors investigated IMGN853 in patients with FRα‐positive solid tumors... 
clinical trial | targeted therapy | folate receptor | phase 1 | antibody‐drug conjugate | antibody-drug conjugate | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Vision Disorders - chemically induced | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Hypophosphatemia - chemically induced | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Neoplasms, Glandular and Epithelial - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Renal Cell - pathology | Maytansine - analogs & derivatives | Keratitis - chemically induced | Maytansine - therapeutic use | Disease Progression | Neoplasms - drug therapy | Maximum Tolerated Dose | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Kidney Neoplasms - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Neoplasms - pathology | Cancer patients | Care and treatment | Pharmacokinetics | Health aspects | Analysis | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9701, pp. 1597 - 1605
Journal Article
Radiotherapy and oncology, ISSN 0167-8140, 2014, Volume 111, Issue 1, pp. 81 - 87
Abstract Objective To investigate the effect of radiation dose-escalation on local control in hypoxic versus non-hypoxic hypoxic tumours defined using [18 F]fluoromisonidazole ([18 F]FMISO) PET... 
Hematology, Oncology and Palliative Medicine | Single dose irradiation | Squamous cell carcinoma | Dose escalation | Local control | [18F]FMISO positron emission tomography | Human tumour xenografts | Hypoxic volume | [F-18]FMISO positron emission tomography | Oncology | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Neoplasm Recurrence, Local - radiotherapy | Cell Hypoxia - radiation effects | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Misonidazole - administration & dosage | Carcinoma, Squamous Cell - diagnostic imaging | Carcinoma, Squamous Cell - radiotherapy | Head and Neck Neoplasms - metabolism | Neoplasm Recurrence, Local - pathology | Squamous Cell Carcinoma of Head and Neck | Radiation-Sensitizing Agents - administration & dosage | Fluorine Radioisotopes - administration & dosage | Neoplasm Recurrence, Local - diagnostic imaging | Female | Neoplasm Recurrence, Local - metabolism | Head and Neck Neoplasms - diagnostic imaging | Misonidazole - analogs & derivatives | Random Allocation | Head and Neck Neoplasms - pathology | Radiopharmaceuticals - administration & dosage | Xenograft Model Antitumor Assays | Head and Neck Neoplasms - radiotherapy | Hypopharyngeal Neoplasms - radiotherapy | Animals | Hypopharyngeal Neoplasms - metabolism | Mice, Nude | Hypopharyngeal Neoplasms - pathology | Radionuclide Imaging | Cell Line, Tumor | Mice | Dose-Response Relationship, Radiation | Hypopharyngeal Neoplasms - diagnostic imaging | Nuclear radiation | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 06/2017, Volume 389, Issue 10088, pp. 2492 - 2502
.... Methods We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Administration Schedule | Humans | Antibodies, Monoclonal - adverse effects | Liver Neoplasms - drug therapy | Male | Response Evaluation Criteria in Solid Tumors | Treatment Outcome | Antineoplastic Agents - administration & dosage | Tumor Burden | Dose-Response Relationship, Drug | B7-H1 Antigen - metabolism | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Nivolumab | Carcinoma, Hepatocellular - pathology | Biomarkers, Tumor - metabolism | Female | Liver Neoplasms - pathology | Aged | Virus diseases | Medical colleges | Care and treatment | Cell death | College teachers | Hepatoma | Comparative analysis | Drug approval | Therapy | Pemphigoid | Intravenous administration | Inhibitor drugs | PD-1 protein | Funding | Liver | Clinical trials | Hepatocellular carcinoma | Lymphocytes T | Infections | Metastasis | Dosage | Cancer therapies | B7 antigen | Acceptability | Incidence | Hepatitis | Liver cancer | Pathways | Quality | Immunotherapy | Safety management | Safety | Expansion | Drug dosages | Liver diseases | Effectiveness | Mortality | Group dynamics | Patients | Hospitals | Inhibitors | Immune checkpoint | Adults | Solid tumors | Hepatitis C virus | Hepatitis C | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 08/2018, Volume 82, Issue 4, pp. 695 - 706
... weeks. Dose escalation was started at 100 mg/m2 over 8 h and the dose increased to 300... 
Hemolysis | Prostate carcinoma | Medicine & Public Health | Oncology | Cancer Research | Curcumin | Phase I cancer trials | Pharmacology/Toxicology | Colon carcinoma | Lipocurc | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Hemolysis - drug effects | Drug-Related Side Effects and Adverse Reactions - blood | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Drug Monitoring - methods | Curcumin - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Neoplasm Invasiveness | Curcumin - pharmacokinetics | Drug Tolerance | Drug-Related Side Effects and Adverse Reactions - etiology | Treatment Outcome | Curcumin - adverse effects | Neoplasm Metastasis - pathology | Colonic Neoplasms - pathology | Aged | Neoplasm Staging | Drug-Related Side Effects and Adverse Reactions - diagnosis | Hemoglobins - analysis | Care and treatment | Safety and security measures | Colon cancer | Analysis | Oncology, Experimental | Hemoglobin | Metastasis | Research | Cancer | Intravenous administration | Tumor markers | Toxicity | Clinical trials | Pharmacology | Patients | Metastases | Anticancer properties | Infusion | Antitumor agents | Intravenous infusion | Safety | Pharmacokinetics | Tumors | Original
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 05/2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article